Leukemia

March 31, 2021
Female doctor consulting with older male patient

Trial Spotlight: Amer Zeidan on the BLAST MRD CML 1 Study for Chronic Myeloid Leukemia

The EA9171 phase II trial aims to determine if adding pembrolizumab immunotherapy to standard-of-care TKI therapy helps more patients achieve undetectable minimal residual disease and allows them to discontinue TKI therapy
December 14, 2020
Clipboard and laptop

Now Enrolling: ECOG-ACRIN Opened Five New Trials in October

The five phase III trials span different cancer types: prostate, leukemia, anal, lung, and myeloma
January 14, 2020

Institution Spotlight: Fox Chase Cancer Center

A Standing Main Member of ECOG-ACRIN since 1971